Under construction – not a live service
Sign in
Taking people in SpainNo phase

Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease

Key facts

Where
Reus, SpainSee the site

Where in Spain

  • Hospital Universitari Sant JoanReus, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Institut Investigacio Sanitaria Pere Virgili
Trial code
NCT05554224
Record updated
13 November 2024
Original description
The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.Read full original descriptionShow less

Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease

The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.

Inclusion: Body mass index greater or equal to 40 kg/m\^2; Body mass index between 35 and 40 kg/m\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus); Positive psychiatric evaluation; Age greater or equal to 18 years old.

Exclusion: Legal or illegal drug consumption, including alcohol; Diagnosis of Hepatitis; Current cancer diagnosis or treatment; Clinical or analytical evidence of severe illness; Clinical or analytical evidence of infectious diseases; Clinical or analytical evidence of terminal illness; Clinical or analytical evidence of chronic or acute inflammation.

ClinicalTrials.gov NCT05554224